Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 174.92 Billion KRW | 2.82% |
| 2022 | 170.13 Billion KRW | 2.27% |
| 2021 | 166.35 Billion KRW | 15.7% |
| 2020 | 143.78 Billion KRW | -5.12% |
| 2019 | 151.54 Billion KRW | 15.47% |
| 2018 | 131.24 Billion KRW | 82.1% |
| 2017 | 72.07 Billion KRW | -42.07% |
| 2016 | 124.4 Billion KRW | -0.9% |
| 2015 | 125.53 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 58.99 Billion KRW | 37.65% |
| 2024 Q1 | 43.99 Billion KRW | -3.39% |
| 2023 FY | 174.92 Billion KRW | 2.82% |
| 2023 Q3 | 42.83 Billion KRW | -4.68% |
| 2023 Q2 | 44.94 Billion KRW | 7.32% |
| 2023 Q1 | 41.87 Billion KRW | 0.41% |
| 2023 Q4 | 45.53 Billion KRW | 6.29% |
| 2022 Q4 | 41.7 Billion KRW | 2.15% |
| 2022 Q1 | 43.47 Billion KRW | -1.35% |
| 2022 Q2 | 44.3 Billion KRW | 1.9% |
| 2022 FY | 170.13 Billion KRW | 2.27% |
| 2022 Q3 | 40.82 Billion KRW | -7.84% |
| 2021 Q4 | 44.06 Billion KRW | 6.36% |
| 2021 Q2 | 41.17 Billion KRW | 4.18% |
| 2021 Q1 | 39.52 Billion KRW | 1.13% |
| 2021 FY | 166.35 Billion KRW | 15.7% |
| 2021 Q3 | 41.43 Billion KRW | 0.62% |
| 2020 Q3 | 37.33 Billion KRW | 9.03% |
| 2020 Q1 | 33.11 Billion KRW | -28.17% |
| 2020 FY | 143.78 Billion KRW | -5.12% |
| 2020 Q4 | 39.08 Billion KRW | 4.68% |
| 2020 Q2 | 34.24 Billion KRW | 3.4% |
| 2019 FY | 151.54 Billion KRW | 15.47% |
| 2019 Q3 | 37.57 Billion KRW | 7.88% |
| 2019 Q2 | 34.83 Billion KRW | 5.43% |
| 2019 Q1 | 33.03 Billion KRW | -2.58% |
| 2019 Q4 | 46.1 Billion KRW | 22.71% |
| 2018 Q1 | 31.15 Billion KRW | -2.12% |
| 2018 FY | 131.24 Billion KRW | 82.1% |
| 2018 Q4 | 33.91 Billion KRW | 4.51% |
| 2018 Q3 | 32.44 Billion KRW | -3.81% |
| 2018 Q2 | 33.73 Billion KRW | 8.29% |
| 2017 Q2 | 10.2 Billion KRW | 0.0% |
| 2017 Q4 | 31.82 Billion KRW | 5.92% |
| 2017 FY | 72.07 Billion KRW | -42.07% |
| 2017 Q3 | 30.04 Billion KRW | 194.42% |
| 2016 FY | 124.4 Billion KRW | -0.9% |
| 2015 FY | 125.53 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -270.184% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 41.298% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 37.176% |
| HANDOK Inc. | 153.76 Billion KRW | -13.76% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -152.734% |
| Yuhan Corporation | 489.94 Billion KRW | 64.297% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 43.013% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -318.589% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 71.369% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -143.009% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -0.447% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -336.735% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -86.984% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -52.474% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -270.184% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -311.865% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -133.082% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -198.284% |
| JW Holdings Corporation | 301.25 Billion KRW | 41.935% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 32.967% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 57.195% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 26.782% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -37.015% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -156.073% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -166.042% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -270.184% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 29.783% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 68.787% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 26.782% |
| Yuhan Corporation | 489.94 Billion KRW | 64.297% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 9.675% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -151.806% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -212.19% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 26.782% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -38.399% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -47.974% |
| CKD Bio Corp. | 25.19 Billion KRW | -594.269% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 21.204% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -5.943% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -163.374% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -37.015% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 50.123% |
| Boryung Corporation | 285.16 Billion KRW | 38.657% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -99.82% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -0.447% |
| JW Lifescience Corporation | 20.26 Billion KRW | -763.34% |